Literature DB >> 20140689

Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2.

Christopher Jonathan Daraius Austin1, B M Mailu, G J Maghzal, A Sanchez-Perez, S Rahlfs, K Zocher, H J Yuasa, J W Arthur, K Becker, R Stocker, N H Hunt, H J Ball.   

Abstract

The first step in the kynurenine pathway of tryptophan catabolism is the cleavage of the 2,3-double bond of the indole ring of tryptophan. In mammals, this reaction is performed independently by indoleamine 2,3-dioxygenase-1 (IDO1), tryptophan 2,3-dioxygenase (TDO) and the recently discovered indoleamine 2,3-dioxygenase-2 (IDO2). Here we describe characteristics of a purified recombinant mouse IDO2 enzyme, including its pH stability, thermal stability and structural features. An improved assay system for future studies of recombinant/isolated IDO2 has been developed using cytochrome b (5) as an electron donor. This, the first description of the interaction between IDO2 and cytochrome b (5), provides further evidence of the presence of a physiological electron carrier necessary for activity of enzymes in the "IDO family". Using this assay, the kinetic activity and substrate range of IDO2 were shown to be different to those of IDO1. 1-Methyl-D-tryptophan, a current lead IDO inhibitor used in clinical trials, was a poor inhibitor of both IDO1 and IDO2 activity. This suggests that its immunosuppressive effect may be independent of pharmacological inhibition of IDO enzymes, in the mouse at least. The different biochemical characteristics of the mouse IDO proteins suggest that they have evolved to have distinct biological roles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140689     DOI: 10.1007/s00726-010-0475-9

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  24 in total

1.  Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

Authors:  Paul B Larkin; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Hiroshi Funakoshi; Toshikazu Nakamura; Robert Schwarcz; Paul J Muchowski
Journal:  Biochim Biophys Acta       Date:  2016-07-05

2.  Differential expression and regulation of Ido2 in the mouse uterus during peri-implantation period.

Authors:  Dang-Dang Li; Xin-Yuan Liu; Chuan-Hui Guo; Liang Yue; Zhan-Qing Yang; Hang Cao; Bin Guo; Zhan-Peng Yue
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-11-19       Impact factor: 2.416

Review 3.  The role of placental tryptophan catabolism.

Authors:  Peter Sedlmayr; Astrid Blaschitz; Roland Stocker
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

4.  Molecular evolution and characterization of fungal indoleamine 2,3-dioxygenases.

Authors:  Hajime J Yuasa; Helen J Ball
Journal:  J Mol Evol       Date:  2010-12-18       Impact factor: 2.395

5.  Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.

Authors:  Katherine A Jackman; Vanessa H Brait; Yutang Wang; Ghassan J Maghzal; Helen J Ball; Gavin McKenzie; T Michael De Silva; Roland Stocker; Christopher G Sobey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-27       Impact factor: 3.000

Review 6.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

7.  Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis.

Authors:  Masakazu Fukunaga; Yasuko Yamamoto; Misaki Kawasoe; Yuko Arioka; Yuki Murakami; Masato Hoshi; Kuniaki Saito
Journal:  J Histochem Cytochem       Date:  2012-08-15       Impact factor: 2.479

8.  Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Authors:  Lauren M F Merlo; Samantha Grabler; James B DuHadaway; Elizabeth Pigott; Kaylend Manley; George C Prendergast; Lisa D Laury-Kleintop; Laura Mandik-Nayak
Journal:  Clin Immunol       Date:  2017-02-20       Impact factor: 3.969

Review 9.  Discovery of IDO1 Inhibitors: From Bench to Bedside.

Authors:  George C Prendergast; William P Malachowski; James B DuHadaway; Alexander J Muller
Journal:  Cancer Res       Date:  2017-12-15       Impact factor: 12.701

10.  Benzo[b]quinolizinium Derivatives Have a Strong Antimalarial Activity and Inhibit Indoleamine Dioxygenase.

Authors:  Esther Jortzik; Kathleen Zocher; Antje Isernhagen; Boniface M Mailu; Stefan Rahlfs; Giampietro Viola; Sergio Wittlin; Nicholas H Hunt; Heiko Ihmels; Katja Becker
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.